GlobeNewswire: ASLAN PHARMACEUTICALS LIMITED Contains the last 10 of 165 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:53:28ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853133/0/en/Aslan-Pharmaceuticals-to-Present-at-the-2nd-Annual-H-C-Wainwright-Autoimmune-and-Inflammatory-Disease-Virtual-Conference-Skin-Diseases-Conditions-and-Disorders.html?f=22&fvtc=4&fvtv=43637Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders2024-03-27T12:07:06Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.]]>https://www.globenewswire.com/news-release/2024/03/12/2844956/0/en/ASLAN-Pharmaceuticals-Announces-5-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering2024-03-12T18:34:49Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares (“ADSs”), each ADS representing twenty-five (25) ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 5,000,000 ADSs. The warrants have an exercise price of $1.00 per ADS, will be exercisable upon issuance, and will expire five years following issuance. The closing of the offering is expected to occur on or about March 14, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/03/11/2843626/0/en/ASLAN-Pharmaceuticals-Provides-TREK-DX-Study-Update-and-Highlights-Potential-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients2024-03-11T11:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, March 11, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has begun to enroll patients in the US under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe atopic dermatitis (AD).]]>https://www.globenewswire.com/news-release/2024/03/06/2841265/0/en/ASLAN-Pharmaceuticals-Announces-New-Translational-Data-on-Eblasakimab-in-COPD-and-Appoints-Leading-Respiratory-Experts-as-Scientific-Advisors.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors2024-03-06T12:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, March 06, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease (COPD) that provides further support for the potential of eblasakimab as a biologic therapy for COPD. In addition, the Company announced the appointment of respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, Associate Professor in Emergency Medicine, Harvard Medical School, and Dr Reynold Panettieri Jr, MD, Vice Chancellor, Translational Medicine and Science, Rutgers University to ASLAN’s Scientific Advisory Board as it evaluates the potential use of eblasakimab as a therapy to treat COPD in addition to atopic dermatitis (AD).]]>https://www.globenewswire.com/news-release/2024/02/29/2837813/0/en/ASLAN-Pharmaceuticals-Receives-Favorable-Opinion-From-the-European-Patent-Office-on-Composition-of-Matter-Patent-Application-for-Farudodstat.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat 2024-02-29T12:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.]]>https://www.globenewswire.com/news-release/2024/01/08/2805232/0/en/ASLAN-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement2024-01-08T11:45:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on January 5, 2024, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the 30 consecutive business days ended January 4, 2024, the Company has not met the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company’s American Depositary Shares (“ADS”). The Company’s ADSs will continue to trade on the Nasdaq Capital Market at this time. The Company’s receipt of the Notice does not impact the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.]]>https://www.globenewswire.com/news-release/2024/01/02/2802571/0/en/ASLAN-Pharmaceuticals-Announces-Participation-in-January-Investor-Conferences.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Announces Participation in January Investor Conferences2024-01-02T12:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its participation in upcoming conferences for January 2024. Listed below are meetings that management will be attending around the week of the J.P. Morgan 42nd Annual Healthcare Conference.]]>https://www.globenewswire.com/news-release/2023/12/12/2794598/0/en/ASLAN-Pharmaceuticals-Provides-Year-End-Update-on-Its-Eblasakimab-and-Farudodstat-Programs.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs 2023-12-12T12:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.]]>https://www.globenewswire.com/news-release/2023/11/20/2783117/0/en/ASLAN-Pharmaceuticals-to-Participate-in-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference2023-11-20T12:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at the Lotte New York Palace Hotel, in New York.]]>https://www.globenewswire.com/news-release/2023/11/03/2773084/0/en/ASLAN-Pharmaceuticals-Presents-New-Data-on-Eblasakimab-in-Atopic-Dermatitis-and-COPD-Translational-Models-at-the-7th-Dermatology-Drug-Development-Summit.html?f=22&fvtc=4&fvtv=43637ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit2023-11-03T11:00:00Z<![CDATA[SAN MATEO, Calif. and SINGAPORE, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced new data was presented at the Dermatology Drug Development Summit (DDDS) that took place in Boston, MA, from October 31 to November 2, 2023. The datasets presented strengthen evidence for eblasakimab’s differentiated mechanism of action in atopic dermatitis (AD), and, for the first time, show application in a new indication, chronic obstructive pulmonary disease (COPD), which can be driven by Type 2 inflammation.]]>